THE MUTAGENICITY AND INTERACTIONS OF 2-(ACETYLAMINO)FLUORENE AND 4-(ACETYLAMINO)FLUORENE WITH CYTOCHROME-P450 AND THE AROMATIC HYDROCARBON RECEPTOR MAY EXPLAIN THE DIFFERENCE IN THEIR CARCINOGENIC POTENCY

A study has been undertaken to identify the properties of 2-(acetylamino)fluorene which render it carcinogenic, in contrast to the 4-isomer, the carcinogenic potential of which is, at best, very weak. Compared to the 4-isomer, 2-(acetylamino)fluorene was a more potent inducer of cytochrome P450 IA (P450 1A) activity, as exemplified by the 0-deethylation of ethoxyresorufin (P450 1A1), the metabolic activation of Glu-P-1 (P450 1A2), and immunoblot analysis. These findings were consistent with the relative affinity of these compounds for the cytosolic aromatic hydrocarbon receptor, determined by the displacement of tetrachlorodibenzo-p-dioxin. In the presence of Aroclor 1254-induced hepatic microsomal and cytosolic preparations 2-(acetylamino)fluorene elicited a potent mutagenic response in the Ames test whereas the 4-isomer, in both cases, elicited a weak mutagenic response. Molecular orbital calculations of the relative energetics of the nitrenium ions revealed that the ion of the 2-isomer was more stable than the nitrenium ion of 4-(acetylamino)fluorene. Control hepatic microsomal and cytosolic fractions could activate 2-(acetylamino)fluorene to mutagens in the Ames test. Pretreatment of animals with 2-(acetylamino)fluorene enhanced both the microsome- and cytosol-mediated activation. In contrast, microsomal and cytosolic fractions from control animals could not activate 4-(acetylamino)fluorene, but following pretreatment with the compound itself, a weak mutagenic response in the presence of microsomes, but not of cytosol, was evident. It is concluded that the markedly higher carcinogenic potential of 2-(acetylamino)fluorene may be, at least partly, due to (a) the higher stability and consequent genotoxicity of its nitrenium ion, (b) the higher degree of the P4501 induction, and (c) its ability to autoinduce its hepatic bioactivation.